https://assets.capyfin.com/instruments/678fdc13234e27009c5d585c.png avatar
Baxter
🇺🇸 NYSE:BAX
View Company
OverviewEarningsDividends
•
Dec 31, 2021

Baxter Q4 2021 Earnings Report

Reported fourth-quarter and full-year results, reflecting growth in sales and earnings per share driven by sustained demand and the acquisition of Hillrom.

Key Takeaways

Baxter International Inc. reported a 10% increase in fourth-quarter sales, reaching $3.5 billion, and a 42% increase in U.S. GAAP earnings per share to $0.47. The results include 19 days of contribution from Hillrom following its acquisition in December 2021. The company's performance reflects strong demand for its medically essential products and the impact of its ongoing transformation.

Fourth-quarter sales increased 10% on a reported basis, 12% on a constant currency basis, and 4% on an operational basis.

U.S. GAAP earnings per share (EPS) were $0.47, and adjusted EPS was $1.04 for the fourth quarter.

Full-year revenue increased 10% on a reported basis, 7% on a constant currency basis, and 5% on an operational basis.

The acquisition of Hillrom is expected to accelerate top- and bottom-line performance and drive innovation in connected care solutions.

Total Revenue
$3.51B
Previous year: $3.18B
+10.5%
EPS
$1.04
Previous year: $0.8
+30.0%
Gross Profit
$1.41B
Previous year: $1.19B
+18.1%
Cash and Equivalents
$2.95B
Previous year: $3.73B
-20.9%
Total Assets
$33.5B
Previous year: $20B
+67.4%

Baxter

Baxter

Baxter Revenue by Geographic Location

Forward Guidance

Baxter expects full-year 2022 sales growth of 24% to 25% on a reported basis and adjusted earnings of $4.25 to $4.35 per diluted share. For the first quarter of 2022, the company anticipates sales growth of 24% to 25% on a reported basis and adjusted earnings of $0.79 to $0.82 per diluted share.

Positive Outlook

  • Sales growth of 24% to 25% on a reported basis for full-year 2022.
  • Adjusted earnings of $4.25 to $4.35 per diluted share for full-year 2022.
  • Sales growth of 24% to 25% on a reported basis for first-quarter 2022.
  • Adjusted earnings of $0.79 to $0.82 per diluted share for first-quarter 2022.
  • Operational sales growth of approximately 4% for full-year 2022.

Challenges Ahead

  • Hillrom is expected to negatively impact sales growth by (25)% - (26)% in Q1 2022
  • Hillrom is expected to negatively impact sales growth by (22)% - (23)% in FY 2022
  • Foreign exchange is expected to positively impact sales growth by 3% in Q1 2022
  • Foreign exchange is expected to positively impact sales growth by 2% in FY 2022
  • Actual U.S. GAAP earnings per share for the first quarter and full year of 2022 may differ significantly from those amounts.

Revenue & Expenses

Visualization of income flow from segment revenue to net income

Company Overview

Full financial data and analysis

View Baxter